Intended for licensed healthcare professionals located in Switzerland.

Swiss Patient Information Swiss Professional Information Report an adverse event
FGFR2 fusion testing
About PEMAZYRE
Efficacy Safety
Dosing and administration Request a meeting Stay informed
Swiss Patient Information Swiss Professional Information Report an adverse event

About
PEMAZYRE®▼

Diamonds Diamonds

About PEMAZYRE (pemigatinib)

DNA Helix

PEMAZYRE is indicated as monotherapy for the treatment of adults with locally advanced, unresectable or metastatic cholangiocarcinoma (CCA) with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, that have progressed after at least one line of systemic therapy (see the “Clinical efficacy” section of the Swiss Professional Information). Contraindications for use include hypersensitivity to the active substance or excipients and concomitant use with St John’s wort.

Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3. It inhibits FGFR phosphorylation and signalling, and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements.

FGFR2 fusion positivity status must be confirmed prior to initiation of PEMAZYRE therapy. Assessment for FGFR2 fusion positivity in tumour specimens should be performed with a validated diagnostic test.

Mechanism of action of pemigatinib

Pemigatinib inhibits FGFR1–3 phosphorylation and signalling

Diagram showing the mechanism of action of pemigatinib

Reference:
PEMAZYRE® (pemigatinib). Swiss Professional Information, November 2022; https://www.swissmedicinfo.ch/ (accessed 16 December 2022).

Learn more about PEMAZYRE (pemigatinib):

Targeted medicine

Discover about FGFR2 fusions in patients with CCA

Targeted medicine FGFR2 fusion testing
Histogram and magnifying glass

Learn about the efficacy of PEMAZYRE

Histogram and magnifying glass Efficacy
Shield and tick

Review the safety data of PEMAZYRE

Shield and tick Safety
Clock and pill

Understand the dosing and administration schedule for PEMAZYRE

Clock and pill Dosing and administration
Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE

PEMAZYRE eDetail
Privacy Policy Cookie Policy Terms of Use If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Marketing authorisation holder:
Incyte Biosciences International Sàrl, Morges

▼ This medicinal product is subject to additional monitoring which will enable quick identification of new safety information.
Healthcare professionals are required to report any suspected new or serious side effects. See the “Undesirable effects” section of the Swiss Professional Information for the terms and conditions for reporting side effects.

Adverse events should also be reported to Incyte immediately by phoning 00800 000 274 23 or via email at eumedinfo@incyte.com.

CH/PEMA/P/23/0001
Date of preparation: January 2023
© 2023, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

Back to top

External link disclaimer

Intended for licensed healthcare professionals located in Switzerland.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event